Purpose The purpose of this study was to determine the 4β-hydroxycholesterol to cholesterol ratio in mothers and neonates at the time of birth and 4 months post-partum. Method 21 mothers and 22 neonates were recruited at the delivery ward at Karolinska University Hospital, Huddinge, Sweden. Blood samples taken from mothers and neonates at birth and 4 months post-partum were analysed for 4β-hydroxycholesterol and cholesterol. Results The median plasma concentration of 4β-hydroxycholesterol was higher in mothers at delivery (50 ng/mL) compared to healthy non-pregnant women (29 ng/mL). The pregnant women had a higher median cholesterol concentration (6.2 mmol/L) compared to healthy non-pregnant women (4.6 mmol/L) but this could only partly explain the increased 4β-hydroxycholesterol. The major cause is an increased CYP3A activity during pregnancy. The median 4β-hydroxycholesterol/cholesterol ratio·10 4 was elevated in mothers at time of birth compared to non-pregnant women (0.19 and 0.15, respectively) but decreased to 0.15 4 months post-partum. Neonates had a median 4β-hydroxycholesterol/cholesterol ratio·10 4 (0.19) comparable to adults already at birth, but lower 4β-hydroxycholesterol (12 ng/mL) and cholesterol (1.8 mmol/L) concentrations. Conclusion Pregnancy leads to increased CYP3A enzyme activity as determined by the 4β-hydroxycholesterol/ cholesterol ratio. Neonates have low 4β-hydroxycholesterol and cholesterol concentrations but similar total CYP3A activity as adults already at birth.
Introduction
About 30% of the cytochrome P450 enzyme content in liver consists of three members of the cytochrome P450 (CYP) 3A subfamily, i.e. CYP3A4, CYP3A5 and CYP3A7 [1] .
There are a number of clinical markers, both endo-and exogenous, used to assess the activity of CYP3A, e.g. the 6β-hydroxycortisol/cortisol ratio in urine [2] , plasma midazolam clearance [3] and the erythromycin breath test [4] . However, none of these markers is easy to use in children, the elderly, in certain groups of vulnerable patients or pregnant women. We have previously shown that the cholesterol metabolite 4β-hydroxycholesterol (4b-OHC) in plasma is a marker of CYP3A enzyme activity [5] [6] [7] [8] [9] . The ratio of 4b-OHC/cholesterol instead of 4b-OHC could be used as a marker of CYP3A under conditions where the cholesterol level is expected to change [10, 11] . There is a previous report on a steady increase in total serum cholesterol throughout almost the whole pregnancy (36 weeks) [12] . The half lives of both 4b-OHC and cholesterol are long: 17 [8] and 72 days [13] respectively, making 4b-OHC a useful marker during long-term rather than short-term studies [14] .
Another 4-hydroxylated metabolite of cholesterol is 4α-hydroxycholesterol (4a-OHC) [15] , which is not formed by CYP3A [9] . It is not known if 4a-OHC might be formed enzymatically, but it is known to be formed by autoxidation [15] .
Pregnancy increases the activity of a number of hepatic enzymes, e.g. CYP3A4 [16] [17] [18] , CYP2D6 [18] [19] [20] and CYP2C9 [16] , while it decreases the activity of others, such as CYP1A2 [18, 21] and CYP2C19 [22] . The altered enzyme activities during pregnancy may be due to increased levels of progesterone and oestrogen and/or fetal enzyme activity [16] . The physiological changes that occur, e.g. reduced intestinal movement, altered gastric pH, increased plasma volume, changes in protein binding and increased renal excretion of unchanged drugs, might also have an effect [16] . However, the mechanisms are not clear and it is likely that different enzymes are affected in different ways by the above-mentioned factors.
There are several chronic conditions for which continuous medication during pregnancy is needed, e.g. epilepsy.
For most drugs there is little information about altered dose requirements during pregnancy despite increasing knowledge about alterations in enzyme activity and increased renal clearance [16] .
In this study we monitored the CYP3A activity in mothers and neonates at birth and 4 months post-partum, as determined by plasma 4b-OHC.
Materials and methods

Recruitment of untreated study subjects
Twenty-one women, mean age 33 years, range 19-41 years and their 22 neonates (one pair of fraternal twins, mean birth weight 3,699 g, range 2,700-4,705 g) were recruited at the delivery ward at Karolinska University Hospital, Huddinge, Sweden over 2 months in 2009. The hospital has approximately 5,000 deliveries per year and the population in the catchment area consists mainly of Caucasians from Europe and the Middle East. The maternal origins in the present study were: Sweden (16), Finland (1), Turkey (1), Iraq (1), Algeria (1), Syria (1) and Chile (1). The paternal origins were: Sweden (16), Algeria (1), Lebanon (1), USA (2), Finland/Germany (1) and Iraq (1) . Two women were treated with thyroxin for hypothyreosis. The remaining women were not treated with any prescribed or over the counter drugs apart from iron, folic acid and/or multivitamins. Three women had been eating grapefruit occasionally during pregnancy. None had been using St. John's Wort. Seven women gave birth by elective caesarean section (CS) and 14 by vaginal delivery. All neonates (12 girls, 10 boys) had normal Apgar scores, birth weight, birth length and head circumference. pH at delivery ranged from 7.16 to 7.44. All neonates had an uneventful neonatal period and were examined clinically by two of the authors (SS and LF) before they were released from the hospital. There were no abnormal signs in 19 of the 22 neonates, while 3 had neonatal jaundice and 1 an unspecific heart murmur.
Eleven children were followed up at the age of about 4 months with a clinical examination by SS and LF. None of the children had suffered from any major disease during the first months of life and noone was on drug treatment. Seven children were still at least partly breast fed.
Eleven mothers refused to allow additional blood samples to be drawn from their children for the 4-month follow-up and thus dropped out of the study.
Recruitment of one carbamazepine-treated mother
A 31-year-old woman treated with carbamazepine for epilepsy with general tonic-clonic seizures for the last 8 years was also recruited at the delivery ward at Karolinska University Hospital, Huddinge, Sweden. She had been seizure-free during the entire pregnancy and for 1 year before. She gave birth by CS due to breech presentation (gestational week 39) to a healthy girl (length 48 cm, weight 3,570 g, head circumference 36 cm, full Apgar score and normal pH). She and her husband were both of Swedish origin and had had one previous child, born in 2003.
This mother-child pair dropped out of the study due to the parents' refusal to allow additional blood samples to be drawn from the child.
All participants gave written informed consent for themselves and their children to participate in the study, which was approved by the ethics committee at Karolinska Institutet, Stockholm.
Cohort of healthy adults and non-pregnant healthy women
We used raw data from a previously published study [9] to calculate the median values of 4a-and 4b-OHC to cholesterol ratios. The cohort of healthy adults consisted of 49 and 76 healthy men and women respectively.
Blood samples
Venous blood samples were drawn in EDTA-containing tubes. After centrifugation the plasma was stored at −70°C prior to analysis. In mothers and children who underwent elective CS a venous blood sample was taken from the mother before surgery. Cord blood was taken immediately after birth. Venous blood samples were also taken from both mothers and children at the 4-month followup. In mothers and children who underwent vaginal delivery venous blood samples were taken from both mothers and children at the time of neonatal screening when the children were 2-3 days old. Venous blood was taken from both mothers and children at the 4-month follow-up.
Analysis of 4a-and 4b-OHC As described previous [9] , 4a-and 4b-OHC were determined by isotope-dilution GC-MS. The between-day variations (CV) for 4a-and 4b-OHC were 10.8% (at 7.2 ng/mL) and 4.9% (at 26.5 ng/mL) respectively. 4a-and 4b-OHC concentrations of 1 ng/mL correspond to 2.5 nmol/L.
Analysis of cholesterol
Cholesterol was determined by an enzymatic method (CHOD-PAPP) run on a Roche/Hitatchi Modular instrument. The between-day variation was 1.3% (at 5 mmol/L).
CYP3A5 genotype
The DNA was prepared from whole blood taken from mothers and children in tubes containing EDTA at the 4-month follow-up (QIAamp DNA Blood Midi Kit; Qiagen, Crawley, UK). Samples were analysed for the single nucleotide polymorphism A6986G (CYP3A5*3) as described before [23] . When the CYP3A5*3 allele was not present the allele was designated CYP3A5*1.
Statistical analysis
All statistical calculations were done using Statistica software, version 8 (StatSoft, Tulsa, OK, USA). The concentration distribution of 4b-OHC is non-normally distributed, which is the reason for the use of the MannWhitney U test and the Wilcoxon matched pairs test in the statistical analyses.
Results
Plasma levels of 4b-OHC in mothers and children
Plasma concentrations of 4b-OHC were higher in mothers at the time of delivery than in a cohort of healthy nonpregnant women (median 50.0 ng/mL, quartile range, QR= 10.7, n=21 and median 28.9 ng/mL, QR=14.4, n=76 [9] respectively). Plasma levels of 4b-OHC in mothers at the time of delivery and 4 months post-partum are presented in Table 1 .
At birth all children had lower plasma 4b-OHC than their mother (Fig. 1, upper panel) and also lower than a cohort of healthy adults (median 18.8 ng/mL, QR=8.6, n=22 and median 27.2 ng/mL, QR=13.8, n=125 respectively). The plasma levels of 4b-OHC in children increased significantly between birth and the 4-month follow up (Table 2) .
Plasma levels of 4a-OHC in mothers and children
Children born by vaginal delivery had twice the plasma levels of 4a-OHC at the time of birth compared with children born by elective CS (30.2 and 14.1 ng/mL respectively; Table 2 , Fig. 1, lower panel) . All children born by vaginal delivery had higher plasma levels of 4a-OHC than their mother, which is in contrast to the children born by elective CS, who all had lower plasma 4a-OHC than their mother. Four months after birth the plasma levels of 4a-OHC in children born by vaginal delivery decreased to the same level as in children born by elective CS (30.2 to 15.1 ng/mL; Table 2 ).
Plasma levels of cholesterol in mothers and children All mothers had significantly higher plasma levels of cholesterol at the time of delivery than a cohort of healthy non-pregnant women (medians 6.2 and 4.6 mmol/L respectively; Table 3 ). Four months post-partum the cholesterol levels had decreased to the same levels as in non-pregnant healthy women (Table 3) .
Children born by elective CS had a median plasma level of cholesterol of 1.8 mmol/L at birth, which had increased to 4.4 mmol/L 4 months later (Table 2) . Unfortunately, we have no data on plasma levels of cholesterol at birth in children born by vaginal delivery due to limited sample volumes. However, 4 months later the cholesterol levels were similar to the levels in children born by CS (4.0 mmol/L).
4b-OHC/cholesterol ratios in mothers and children Mothers had significantly higher 4b-OHC/cholesterol ratios·10 4 around delivery compared with a cohort of nonpregnant healthy women (median 0.19 and 0.15 respectively; Table 3 ). Four months post-partum there was no longer any significant difference between the 4b-OHC/cholesterol ratios in mothers and non-pregnant healthy women.
There was no difference in the 4b-OHC/cholesterol ratios·10 4 at birth between children born by elective CS and a cohort of 125 healthy adults [9] (0.19 and 0.15 respectively).
At the age of 4 months the children (n=11) had a significantly higher 4b-OHC/cholesterol ratio·10 4 than the cohort of healthy adults (0.20 and 0.15 respectively; MannWhitney, p<0.01).The cohort of 125 healthy adults consisted of 49 men and 76 women, with median concentrations of 4b-OHC and cholesterol of 24.2 ng/mL and 4.30 mmol/L respectively in men and 28.9 ng /mL and 4.58 mmol/L respectively in women. The 4b-OHC/cholesterol ratios·10 4 in men and women were 0.14 and 0.16 respectively. 4a-OHC/cholesterol ratios in mothers and children Mothers (n=21) had significantly higher 4a-OHC/cholesterol ratios both at time of delivery and 4 months postpartum compared with a cohort of non-pregnant healthy women (Table 3) .
Children born by elective CS had a significant decrease in the 4a-OHC/cholesterol ratio·10 4 between birth and the 4-month follow-up (0.20 to 0.09, n=6; Table 2 ). However, the ratio·10 4 was still significantly higher in the children (n= 11) than in a cohort of healthy adults (0.09, QR=0.03, n=11 and 0.03, QR=0.01, n=125 respectively; Mann-Whitney p< 0.001). The 4a-OHC/cholesterol ratio·10 4 for the 76 healthy women was 0.03. Plasma levels of 4b-OHC, 4a-OHC, cholesterol, 4b-OHC/ cholesterol ratio and 4a-OHC/cholesterol ratio after carbamazepine treatment during pregnancy A mother treated with carbamazepine during the entire pregnancy had a very high plasma level of 4b-OHC 2 days after an elective CS (392 ng/mL) compared with untreated mothers (elective CS, 53.2 ng/mL; Table 1 ). The level of 4b-OHC in the cord blood plasma of the child was higher compared with children born by elective CS of untreated mothers (76 ng/mL and 12.0 ng/mL respectively).
The carbamazepine-treated mother had a plasma level of 4a-OHC that was comparable to that of untreated mothers giving birth by elective CS (18.9 and 16.8 ng/mL respectively).
The newborn child had a cord blood plasma level of 4a-OHC comparable to that of children born by elective CS of untreated mothers (19.1 and 14.1 ng/mL respectively). The carbamazepine-treated mother and her child had cholesterol levels of 5.5 and 1.9 mmol/L respectively.
The 4b-OHC/cholesterol ratio·10 4 in this mother was about 9-fold higher than in untreated mothers (1.8 and 0.19 respectively). The child had a close to 5-fold higher 4b- Vaginal delivery: blood samples were taken at the neonatal screening 2-3 days after birth p values from the Mann-Whitney U test
The change in concentrations of 4a-OHC, 4b-OHC and cholesterol from delivery to 4 months later were statistically tested by the Wilcoxon matched pairs test p values are reported as *p<0.05, **p>0.05 and in the text in the section Plasma levels of cholesterol in mothers and children OHC/cholesterol ratio·10 4 compared with children of untreated mothers (0.99 and 0.19 respectively).
Discussion
We have previously shown that 4b-OHC is a marker of CYP3A activity and that there is a weak correlation between 4b-OHC and cholesterol [7] , indicating that it is the CYP3A activity and not the cholesterol concentration that determines the level of 4b-OHC. The use of the 4b-OHC/cholesterol ratio instead of 4b-OHC has been suggested for conditions where the cholesterol concentration is expected to change [10] . Pregnancy is one such a condition [12, 24] .
In the present study we show that pregnancy led to increased CYP3A enzyme activity, as determined by higher plasma 4b-OHC/cholesterol ratios in mothers at the time of delivery compared with a cohort of nonpregnant healthy women. The increased enzyme activity during pregnancy has been shown previously using midazolam as a CYP3A marker [17] . In that study it was suggested that the CYP3A enzyme activity had returned to baseline within 6-10 weeks post-partum, which is in line with the present study, where there was no difference between 4b-OHC/cholesterol ratios in mothers 4 months post-partum and non-pregnant healthy women.
Other markers of CYP3A enzyme activity have also shown increased enzyme activity during pregnancy, e.g. the dextromethorphan/3-hydroxymorphinan ratio in 24-h urine [18] and the 6β-hydroxycortisol/cortisol ratio in 4-h urine [25] . However, the dextrmethorphan/3-hydroxymorphinan ratio in plasma [19] and the 6β-hydroxycortisol/cortisol ratio in spot urine [26] showed marginal or no effect on the CYP3A activity during pregnancy.
This may be a result of the different substrate specificities of the different CYP3A enzymes. Midazolam is mainly a marker of CYP3A4 [27] , while the 4b-OHC/cholesterol ratio and 4b-OHC are markers of the combined activity of CYP3A4 and CYP3A5 [7, 28] . In the present study, only 3 mothers and 3 children had one functional CYP3A5*1 allele, thus expressing CYP3A5. The CYP3A5*3 allele was determined in only 10 mothers and 11 children because of the high drop-out rate at the 4-month follow up when the genotyping was scheduled. Owing to the small dataset, statistical analyses were not performed.
The plasma 4b-OHC concentration was lower in neonates than in healthy adults. This may be due to the low plasma cholesterol level in the newborns, which increased rapidly and more than doubled during the first 4 months. The 4b-OHC/cholesterol ratio in neonates was already comparable at birth to that of healthy adults and did not change during the next 4 months. A previous study on CYP3A4 activity in infants reported low activity at birth and progressively increasing activity, reaching 72% of that in adults after 1 year [29, 30] . Similar findings have been reported by others [31, 32] . The difference in CYP3A activity determined by 4b-OHC or different probe drugs may be explained by the different substrate specificities of the CYP3A members. There is no information at present as to whether CYP3A7 catalyses the conversion of cholesterol to 4b-OHC in vivo. CYP3A7 is abundant in fetal and neonatal livers and may account for more than 50% of total P450 [33] . If CYP3A7 is an active cholesterol 4β-hydroxylase the 4b-OHC levels determined would be a sum of CYP3A4, CYP3A5 and CYP3A7 activity. A postnatal decrease in CYP3A7 activity and a concomitant increase in CYP3A4 activity would thus not be possible to monitor with 4b-OHC since the total CYP3A activity would stay approximately constant.
The plasma levels of cholesterol were significantly higher in mothers compared with the cohort of nonpregnant women. Four months post-partum the cholesterol levels had declined and were not significantly different from the level in the cohort of non-pregnant women. There are previous reports on a steady increase of total serum cholesterol throughout almost the whole pregnancy [12] .
An interesting finding in the present study is the increased level of 4a-OHC at birth in children born by vaginal delivery. After 4 months the 4a-OHC level had decreased to the same level found in children born by CS. 4a-OHC is known to be formed by cholesterol autoxidation [9] during oxidative stress, but it is not known whether it can be formed enzymatically as well. There are inconsistencies in the literature on the oxidative effect on mother and child by uncomplicated vaginal delivery or CS [34] [35] [36] [37] [38] [39] [40] , possibly due to the use of different markers. The elevated levels of 4a-OHC in children born by vaginal delivery may be a consequence of increased oxidative stress during birth. At present nothing is known about the potential effects of elevated 4a-OHC levels. If the increased level of 4a-OHC in children born vaginally is due to cholesterol autoxidation, 4b-OHC is expected to be formed to a similar degree by this mechanism. It is noteworthy that children born by vaginal delivery had higher 4b-OHC levels at birth than children born by CS.
One possible weakness of our study is the time difference between samples taken from mothers and neonates with elective CS and vaginal delivery, i.e. at birth and 2 days after birth respectively. However, rapid changes in the levels of 4b-OHC and cholesterol during a 2-day period are unlikely because of the half-lives of several days of both substances [8, 13] . It should also be noted that the number of observations is small, which limits the strength of the statistical analyses.
In conclusion, pregnancy led to increased CYP3A enzyme activity in mothers compared with non-pregnant women, as determined by elevated plasma 4b-OHC/ cholesterol ratios.
Neonates had lower 4b-OHC and cholesterol concentrations than adults, but the 4b-OHC/cholesterol ratio was comparable to that of adults. 4b-OHC is an endogenous CYP3A marker that can be used in situations where probe drugs cannot be given, e.g. in pregnant women and in infants. Comparisons of 4b-OHC and drug metabolism are needed to validate 4b-OHC as a CYP3A marker in neonates.
